-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Feladilimab in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Feladilimab in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Feladilimab in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewRett Syndrome – Drugs In Development, 2024
Empower your strategies with our Rett Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III or the plateau, and Stage IV or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems,...
-
Product Insights
NewWilson Disease – Drugs In Development, 2024
Empower your strategies with our Wilson Disease – Drugs In Development, 2024 report and make more profitable business decisions. Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and vitamin E supplements. The Wilson Disease drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trodusquemine in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trodusquemine in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Trodusquemine in Human...
-
Product Insights
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and Vitamin E supplements. The Wilson disease pipeline market research report provides comprehensive information on the therapeutics under development for Wilson disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – trodusquemine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry trodusquemine Drug Details Trodusquemine (MSI-1436) is under development for the treatment of metastatic breast...
-
Product Insights
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome – Drugs In Development, 2022, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape. Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss...
-
Product Insights
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and...